Scientific Advisory Board

Stephen M. Cox, M.D.
President & Medical Director, National Anxiety Foundation

Stephen M. Cox, MD is President of the National Anxiety Foundation and Assistant Clinical Professor of Psychiatry at the University of Kentucky College of Medicine. A board-certified psychiatrist, Dr. Cox has been in private practice for 37 years. He received his medical degree from the University of  Kentucky College of Medicine and completed his psychiatry residency at the University of Kentucky Medical Center.

Dr. Cox has served as a member of the editorial board of Annals of Clinical Psychiatry and on the board of directors of the American Academy of Clinical Psychiatry. He has also served on the advisory committee of the National Panic Disorder Public Education Project of the National Institute of Mental Health. Dr. Cox has written extensively on anxiety disorders and has been featured in discussions on this topic on television, radio, and in print media. He has presented his research on anxiety at the US Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health.

Dr. Cox has been, and continues to be advised by the following internationally recognized experts on anxiety disorders, who generously serve as unpaid volunteers on the Scientific Advisory Board of the National Anxiety Foundation.

Robert DuPont, M.D. (past)
For more than 40 years, Robert L. DuPont, M.D. has been a leader in drug abuse prevention and treatment. Among his many contributions to the field is his leadership as the first Director of the National Institute on Drug Abuse (1973-1978) and as the second White House Drug Chief (1973-1977). From 1968 to 1970 he was Director of Community services, for the District of Columbia Department of Corrections, heading parole and half-way house services

From 1970 to 1973, he served as administrator of the District of Columbia Narcotics Treatment Administration (NTA), the city-wide drug abuse treatment program that was the model for the federal government’s massive commitment to drug abuse treatment in the early 1970s. Following this distinguished public career, in 1978 Dr. DuPont became the founding president of the Institute for Behavior and Health, Inc.

Dr. DuPont has written for publication more than three hundred professional articles and fifteen books and monographs on a variety of health-related subjects. His books include Getting Tough on Gateway Drugs: A Guide for the Family, A Bridge to Recovery: An Introduction to Twelve-Step Programs and The Selfish Brain: Learning from Addiction. In 2005, Hazelden, the nation’s leading publisher of books on addiction and recovery, published three books on drug testing by Dr. DuPont: Drug Testing in Drug Abuse Treatment, Drug Testing in Schools, and Drug Testing in the Criminal Justice System.

Throughout his decades of work in addiction prevention, Dr. DuPont has served in many capacities. His activities in the American Society of Addiction Medicine (ASAM) include chairing the forensic science committee and he is a Life Fellow. He is also a Life Fellow of the American Psychiatric Association (APA) and was chairman of the Drug Dependence Section of the World Psychiatric Association (WPA) from 1974 to 1979. In 1989 he became a founding member of the Medical Review Officer Committee of ASAM. He is an International Fellow of Drug Free Australia.

A graduate of Emory University, Dr. DuPont received an M.D. degree in 1963 from the Harvard Medical School. He completed his psychiatric training at Harvard and the National Institutes of Health in Bethesda, Maryland. Dr. DuPont maintains an active practice of psychiatry specializing in addiction and the anxiety disorders and has been Clinical Professor of Psychiatry at the Georgetown University School of Medicine since 1980. He is vice president of Bensinger, DuPont and Associates (BDA), a leading national consulting firm dealing with substance abuse, founded in 1982 by Dr. DuPont and Peter Bensinger, former Director of the Drug Enforcement Administration.

Dr. DuPont’s signature role throughout his career has been to focus on the public health goal of reducing the use of illegal drugs. He currently serves on the boards of directors of the Kolmac Foundation, the American Council on Science and Health, the National Anxiety Foundation and the World Federation Against Drugs.

Read a 2010 interview with Dr. DuPont by William L. White, MA featured in Counselor magazine, “On Addiction, Treatment, Recovery and a Life of Service.”

Read this Article:

Roy Eskapa, Ph.D. (Capetown, South Africa)

Roy Eskapa, PhD (1955) was born in South Africa. Graduated from the International School, Geneva (1974), Reed College, BA (1978), California School of Professional Psychology, PhD (1983) Post-doc in Multimodal Therapy with Prof Arnold Lazarus. NJ License 1988, Chartered Psychologist and Associate Fellow British Psychological Society, 1983. Worked with the late Dr. David Sinclair (National Public Health Institute, Finland) 1989 – 2015 on deprivation effects and pharmacological extinction for addictions. Published his first book on pharmacological extinction or The Sinclair Method (TSM) – The Cure for Alcoholism, Benbella Books, Dallas, 2008. Updated edition with Introduction by actress Claudia Christian released 6 November, 2012

Donald W. Goodwin, M.D. (in memorium)
Sentiments by Samuel B. Guze, MD of Washington University about Dr. Goodwin:

“Dr. Goodwin graduated from Baker University in Kansas in 1953. He received his MD degree in 1964 from the University of Kansas. After medical school, he served as a resident in psychiatry at Washington University in St Louis, MO, and remained there as a member of the faculty until 1976, when he moved back to the University of Kansas. He served in the US Army during the Korean War and worked as a newspaperman in New York City before deciding to return to Kansas for premedical courses and then medical school.

Dr. Goodwin’s career was noteworthy for combining his considerable skill as a writer and his interest in psychiatric research with a particular focus on alcoholism. He was a pioneer in the study of the genetics of alcoholism, beginning his work when he developed a collaborative effort between colleagues at Washington University and at the University of Copenhagen in Denmark. The latter group had acquired a roster of adoptees in Copenhagen and Denmark and worked with colleagues at Washington University, headed by Dr. Goodwin, to carry out extensive follow-up and family studies. Their results, clearly indicating a hereditary predisposition to alcoholism, have since been confirmed many times over the world. Dr. Goodwin authored many books and scientific articles. He received numerous awards and international recognition, especially for his aforementioned work in alcoholism.

Dr. Goodwin had a lifelong interest in writing and literature, and he was a marvelous raconteur. He had a contagious sense of humor and loved to converse with a wide range of friends and acquaintances over a broad range of subjects, including biographies of writers, history, politics, and the future of psychiatry. …”

We appreciate so much Dr. Guze’s illuminating remarks regarding our dear friend, Donald. We at NAF will forever be grateful to Donald for his great help to us in our founding years. Stephen Cox M.D.

Donald F. Klein, M.D., D.Sc.
Senior Scientific Advisor, Child Mind Institute

Donald Klein, MD, DSc, has been a dominant figure in the field of treatment science and a prime mover in the improvement of diagnosis and our understanding of psychiatric illness for over half a century. His pioneering work applying both psychological and pharmaceutical approaches to therapy has become standard procedure in the treatment of psychiatric disorders and chronic emotional distress. Dr. Klein is Professor Emeritus in the Department of Psychiatry at Columbia University College of Physicians and Surgeons, former director of research at the New York State Psychiatric Institute, a research psychiatrist at the Nathan Kline Institute of Psychiatric Research, and a Senior Scientific Advisor at the Child Mind Institute.

As Senior Scientific Advisor at the Child Mind Institute, Dr. Klein works with Michael P. Milham, MD, PhD, the Director of the Center for the Developing Brain on establishing a research strategic plan. Dr. Klein also works with Child Mind Institute clinicians to evaluate the effectiveness of their new and innovative treatments and ability to take them to a national scale.

Dr. Klein entered medical training in 1952 with the intention of becoming a psychoanalyst, but soon became particularly interested in the burgeoning field of psychopharmacology. This interest bloomed into an influential clinical and research career that has shaped our understanding and treatment of childhood anxiety and hyperactivity (ADHD), adult and childhood asocial schizophrenia, unipolar and bipolar depression, and social phobia. Dr. Klein’s 1960 discovery that the drug imipramine had an anti-panic effect not only led to helpful treatments—it eventually defined a disorder and introduced the concept of the biological bases of psychiatric illness.

Dr. Klein was a leading contributor to the third addition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) in 1980, which ushered in the age of modern psychiatry. He co-authored the first textbook of clinical psychopharmacology, Diagnosis and Drug Treatment in Psychiatric Disorders. His many editorial assignments include extensive experience with the Archives of General Psychiatry, and he has sat on the editorial board of 10 peer review journals. Dr. Klein has also made informing the general public of advances in psychiatric treatment one of his priorities. Of his 19 books, two are specifically aimed at educating readers about biopsychiatry, psychotherapy, and depression: Mind, Mood and Medicine: A Guide to the New Biopsychiatry and Understanding Depression.

Judith L. Rapoport, M.D. (past advisor)
Professor of Psychiatry, George Washington University School of Medicine, Washington, DC; Chief, Child Psychiatry Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland. Her laboratory investigated the clinical phenomenology, neurobiology, and treatment of psychiatric disorders in children. In addition, Dr. Rapoport was a professor of psychiatry at George Washington University School of Medicine and clinical professor of psychiatry and pediatrics at Georgetown University Medical School. Among her writings is the first book on OCD for general readership entitled The Boy Who Couldn’t Stop Washing: The Experience and Treatment of Obsessive-Compulsive Disorder.

Franklin Schneier, M.D. (past advisor)
Research Psychiatrist, Clinical Therapeutics,
New York State Psychiatric Institute

Dr. Franklin Schneier is a Special Lecturer at Columbia University College of Physicians and Surgeons and Research Psychiatrist in the Anxiety Disorders Clinic at New York State Psychiatric Institute. Dr. Schneier is a graduate of Yale College and Cornell University Medical College, and he completed his residency in psychiatry at Mt. Sinai Medical Center. He came to the Anxiety Disorders Clinic in 1987 as a research fellow, later serving as associate director of the clinic and currently as a research psychiatrist. He is a member of the Scientific Advisory Board of the Anxiety Disorders Association of America.

Dr. Schneier’s research has focused on the diagnosis, treatment, and pathophysiology of social anxiety disorder, other anxiety disorders, and depression. He has been the recipient of Federal funding to conduct clinical trials establishing the efficacy of medications and combined medication-cognitive-behavioral treatments for social anxiety disorder and PTSD. He is also trained in cognitive-behavioral therapy. Dr. Schneier has also been funded by NIMH to use PET and fMRI imaging techniques to study social anxiety disorder and depression. He is author of more than 150 scholarly publications and a book for general audiences, The Hidden Face of Shyness.

Dr. Schneier also maintains a private practice in general psychiatry, including diagnostic assessment and consultations, psychopharmacology and cognitive-behavioral therapy. He combines a focus on evidence-based treatment with recognition of the need for a creative and individualized approach to the unique aspects of each person.

Education and Training
Undergraduate:  Yale University, B.S., 1979
Medical School:  Cornell Medical College, M.D., 1983
Internship:  Tufts-New England Medical Center, Psychiatry, 1983 – 1984
Residency:  Mt. Sinai Medical Center, Psychiatry, 1984 – 1987
Fellowship:  N.Y. State Psychiatric Institute, Clinical Research,  1987- 1990
Board Certifications:  American Board of Psychiatry and Neurology

• Anxiety Disorders
• Psychopharmacology
• Cognitive-Behavioral Therapy

David V. Sheehan, M.D., M.B.A.
Distinguished University Health Professor Emeritus at University of South Florida College of Medicine Tampa, Florida.

David V. Sheehan M.D., M.B.A. is recognized as one of the world’s leading researchers in anxiety disorders. He has written over 500 abstracts and 250 publications including a bestseller The Anxiety Disease.

Dr. Sheehan is the author of several widely used rating scales including the Sheehan Disability Scale (SDS), the Sheehan Irritability Scale (SIS) and the Sheehan Suicidality Tracking Scale (S-STS). He is also the author (with Professor Yves Lecrubier) of the Mini International Neuropsychiatric Interview (MINI) – a short, structured diagnostic interview for psychiatric disorders that has now been used in research and clinical practice in 100 countries.

Dr. Sheehan has served on the editorial boards of many journals. He has been a consultant to the World Health Organization, the World Federation of Societies of Biological Psychiatry and the International Academy for Biomedical and Drug Research, the U.S. Congress, the US Food and Drug Administration, and the National Institute for Mental Health (NIMH). He has also served on the national and international advisory boards of numerous pharmaceutical companies and of nonprofit foundations.

Dr. Sheehan has been invited to give lectures in 66 countries on anxiety and mood disorders, psychopharmacology and biological psychiatry. He was elected as a member of the American College of Psychiatrists and is a Distinguished Fellow of the American Psychiatric Association and is a Charter Member of the National Academy of Inventors.

Distinguished University Health Professor Emeritus
University of South Florida
2011 – Present

Professor of Psychiatry & Director of The Depression & Anxiety Disorders Research Institute
University of South Florida College of Medicine
1985 – 2010 (25 years)

Assistant Professor of Psychiatry
Harvard Medical School
1980 – 1985 (5 years) Director Anxiety Research, Massachusetts General Hospital, Boston

The Anxiety Disease, Simon & Schuster, 1986. A best-selling book on anxiety for lay public – sold over a 1/2 million copies.

University of South Florida – College of Business Administration
M.B.A. (summa cum laude), Business Administration and Management, General
1993 – 1995

University College Dublin Medical School
M.B., B.Ch., B.A.O., Medicine
1964 – 1970

Clongowes Wood College, Co. Kildare, Ireland
1959 – 1964

David Sinclair, Ph.D. (in memorium)
The National Public Health Institute, Helsinki, Finland;
The late (2015) David Sinclair, PhD, began research on the causes of excessive alcohol drinking as a University of Cincinnati undergraduate. Among his discoveries was the Alcohol Deprivation Effect (ADE)—now widely recognized by addiction medicine as central to explaining why the vast majority of alcoholics relapse after traditional abstinence-based treatments. In other words, weeks of forced abstinence—as used in conventional detoxification and detention treatments—instead of being beneficial, actually increase alcohol craving. After getting his doctorate in 1972 from the University of Oregon on the ADE, Dr. Sinclair immediately went to Helsinki to work at Alko Laboratories (now part of Finland’s National Public Health Institute)—probably the best place in the world for finding a better treatment for alcoholism.

His solution, pharmacological extinction, became apparent only after he wrote The Rest Principle: A Neurophysiological Theory of Behavior, a book showing how the nervous system strengthens behaviors that stop hunger, thirst, pain, or release endorphins, and extinguishes behaviors that no longer produce reinforcement. He subsequently worked on the clinical trials proving the concept and practical implementation of the treatment in patients. He was researching extensions of the treatment for alcoholism to other addictions, and on a new treatment for panic disorders when he was taken from us.

We lost our dear friend in 2015. He was an irreplaceable giant.

Stephen Stahl, M.D., Ph.D.
Adjunct Professor of Psychiatry University of California San Diego, School of Medicine. Founder and leader of NEI, America’s great medical education resource for neuropsychopharmacology.

An author of over 425 articles and more than 1500 scientific presentations and abstracts, Dr. Stahl is an internationally recognized clinician, researcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has edited five books and written 25 more, including the best-selling textbook Stahl’s Essential Psychopharmacology, now in its third edition, and the best-selling clinical manual, Essential Psychopharmacology Prescriber’s Guide, also in its third edition. Dr. Stahl has conducted numerous research projects during his career awarded by NIMH, the Veterans Administration and the pharmaceutical industry.

Dr. Stahl is Adjunct Professor of Psychiatry at the University of California, San Diego and Honorary Visiting Senior Fellow, University of Cambridge, U.K. He has held faculty positions at Stanford University, the University of California, Los Angeles, the Institute of Psychiatry London and the Institute of Neurology London. Dr. Stahl was also Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the U.K. for several years. His major interests are dedicated to producing and disseminating educational information about diseases and their treatment in psychiatry and neurology with a special emphasis on multimedia, the Internet and teaching how to teach.

Background and Education
Dr. Stahl received his undergraduate and medical degrees from Northwestern University in Chicago and his PhD in pharmacology and physiology from the University of Chicago. He has trained in three specialties: Internal Medicine at the University of Chicago, Neurology at the University of California, San Francisco and Psychiatry at Stanford. He is board certified in psychiatry.

Rachel Yehuda, Ph.D. (past)
Asst. Professor of Psychiatry, Mount Sinai School of Medicine.

Rachel Yehuda, PhD, Professor of Psychiatry and Neuroscience, is the Director of the Traumatic Stress Studies Division at the Mount Sinai School of Medicine which includes the PTSD clinical research program and the Neurochemistry and Neuroendocrinology laboratory at the James J. Peters Veterans Affairs Medical Center. Dr. Yehuda is a recognized leader in the field of traumatic stress studies. She has authored more than 250 published papers, chapters, and books in the field of traumatic stress and the neurobiology of PTSD.  Her current interests include the study of risk and resilience factors, psychological and biological predictors of treatment response in PTSD, genetic and epigenetic studies of PTSD and the intergenerational transmission of trauma and PTSD. She has an active federally-funded clinical and research program that welcomes local and international students and clinicians.

Dr. Yehuda’s research on cortisol and brain function has revolutionized the understanding and treatment of PTSD worldwide and has been awarded the renowned Max Planck Institute for Psychiatry (Munich, Germany) 2004 Guest Professorship. The appointment signifies a special recognition of the outstanding research she has been performing in the field of neuroscience in the context of studies on causality of psychiatric disorders over the years.

Dr. Yehuda received her PhD in Psychology and Neurochemistry and her MS in Biological Psychology from the University of Massachusetts at Amherst and completed her postdoctoral training in Biological Psychiatry in the Psychiatry Department at Yale Medical School.